IBRUTINIB HEMISULPHATE

摘要

The invention relates to a novel crystalline solid form of ibrutinib in the form of a pharmaceutically acceptable salt with sulphuric acid and to methods of its preparation. This salt is prepared by a reaction of ibrutinib in the free base form (formula I) with sulphuric acid in a suitable solvent or mixtures of solvents. The prepared novel crystalline solid form has suitable physical-chemical characteristics for use in the pharmaceutical industry and formulation of new dosage forms.